Early detection and management of the high-risk patient with elevated blood pressure

References

• AndersonOKAlmgrenTPerssonBSurvival in treated hypertension: follow-up study after two decadesBMJ1998317167719665894
   PubMedGoogle Scholar
• ARIC InvestigatorsAssociation of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in the Communities (ARIC) studyAm J Epidemiol1997146483949290509
   PubMed Web of Science ®Google Scholar
• BadimonJJFusterVChesebroJHCoronary atherosclerosis: a multifactorial diseaseCirculation199387SupplII3168443920
   PubMedGoogle Scholar
• BarnettAHBainSCBouterPAngiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathyN Engl J Med200435119526115516696
   PubMed Web of Science ®Google Scholar
• BlakeGJRifaiNBuringJEBlood pressure, C-reactive protein, and risk of future cardiovascular eventsCirculation20031082993914638538
   PubMed Web of Science ®Google Scholar
• BotsMLHoesAWKoudstaalPJCommon carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam studyCirculation199796143279315528
   PubMed Web of Science ®Google Scholar
• CasalePNDevereuxRBMilnerMValue of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive menAnn Intern Med198610517382942070
   PubMed Web of Science ®Google Scholar
• ChobanianAVBakrisGLBlackHRThe Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 reportJAMA200328925607212748199
   PubMed Web of Science ®Google Scholar
• CuspidiCMeaniSFusiVMetabolic syndrome and target organ damage in untreated essential hypertensivesJ Hypertens2004221991815361772
   PubMed Web of Science ®Google Scholar
• DahlöfBDevereuxRBKjeldsenSECardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLancet2002359995100311937178
   PubMed Web of Science ®Google Scholar
• DahlöfBSeverPSPoulterNRPrevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentric randomised controlled trialLancet200536689590616154016
   PubMed Web of Science ®Google Scholar
• De BackerGAmbrosioniEBroch-JohnsenKEuropean guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical PracticeEur J Cardiovasc Prev Rehab200310Suppl 1S178
   PubMedGoogle Scholar
• DevereuxRBAldermanMHRole of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid eventsCirculation1993881444558403291
   PubMed Web of Science ®Google Scholar
• DevereuxRBDahlöfBGerdtsERegression of left ventricular hypertrophy by losartan compared with atenolol. The Losartan Intervention For Endpoint reduction in hypertension (LIFE) trialCirculation200411014566215326072
   PubMed Web of Science ®Google Scholar
• Guidelines SubcommitteeEuropean Society of Hypertension - European Society of Cardiology Guidelines for the management of arterial hypertensionJ Hypertens20032110115312777938
   PubMed Web of Science ®Google Scholar
• GrundySMHypertriglyceridemia, insulin resistance, and the metabolic syndromeAm J Cardiol19998325F9
   PubMed Web of Science ®Google Scholar
• HanssonLZanchettiACarruthersSGEffects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study GroupLancet19983511755629635947
   PubMed Web of Science ®Google Scholar
• IslesCGWalkerLMBeeversGDMortality in patients of the Glasgow Blood Pressure ClinicJ Hypertens19864141563711657
   PubMed Web of Science ®Google Scholar
• JensenJSFeldt-RasmussenBStrandgaardSArterial hypertension, microalbuminuria, and risk of ischemic heart diseaseHypertension20003589890310775558
   PubMed Web of Science ®Google Scholar
• JuliusSKjeldsenSEWeberMOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialLancet200436320223115207952
   PubMed Web of Science ®Google Scholar
• KlingbeilAUSchneiderMMartusPA meta-analysis of the effects of treatment on left ventricular mass in essential hypertensionAm J Med200311541612867233
   PubMed Web of Science ®Google Scholar
• KorenMJDevereuxRBCasalePNRelation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertensionAnn Intern Med1991114345521825164
   PubMed Web of Science ®Google Scholar
• ManciniJDahlöfBDíezJSurrogate markers for cardiovascular disease. Structural markersCirculation2004109Suppl IVIV-223015226248
   PubMedGoogle Scholar
• MuleGCottoneSNardiEMetabolic syndrome in subjects with essential hypertension: relationsship with subclinical cardiovascular and renal damageMinerva Cardioangiol2006541739416778751
   PubMedGoogle Scholar
• NakaoNYoshimiuraAMoritaHCombination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trialLancet20033611172412531578
   PubMed Web of Science ®Google Scholar
• NissenSEMuratELibbyPEffect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT Study: A randomized controlled trialJAMA200429222172615536108
   PubMed Web of Science ®Google Scholar
• ParvingHHLehnertHBrochner-MortensenJThe effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetesN Engl J Med2001345870811565519
   PubMed Web of Science ®Google Scholar
• PontremolliRRaveraMBezanteGPLeft ventricular geometry and function in patients with essential hypertension and microalbuminuriaJ Hypertens199917993100010419073
   PubMed Web of Science ®Google Scholar
• PontremolliRLeonciniGRaveraMMicroalbuminuria, cardiovascular, and renal risk in primary hypertensionJ Am Soc Nephrol200213S1697212466308
   PubMed Web of Science ®Google Scholar
• ReboldiGGentileGAngeliMicroalbuminuria and hypertensionMinerva Med2005962617516179893
   PubMedGoogle Scholar
• RidkerPMRifaiNRoseLComparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular eventsN Engl J Med200234715576512432042
   PubMed Web of Science ®Google Scholar
• RidkerPMClinical application of C-reactive protein for cardiovascular disease detection and preventionCirculation2003107363912551853
   PubMed Web of Science ®Google Scholar
• RuggenentiPFassiAIlievaAPPreventing microalbuminuria in type 2 diabetesN Engl J Med200435119415115516697
   PubMed Web of Science ®Google Scholar
• SchillaciGPirroMVaudoGPrognostic values of the metabolic syndrome in essential hypertensionJ Am Coll Cardiol20044318172215145106
   PubMed Web of Science ®Google Scholar
• SchrierRWEstacioROEslerAEffects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokesKidney Int20026110869711849464
   PubMed Web of Science ®Google Scholar
• ShigematsuYHamadaMOhtsukaTLeft ventricular geometry as an independent predictor for extracardiac target organ damage in essential hypertensionAm J Hypertens199811117179799033
   PubMed Web of Science ®Google Scholar
• SierraCde la SierraAParéJCCorrelation between silent cerebral white matter lesions and left ventricular mass and geometry in essential hypertensionAm J Hypertens2002155071212074351
   PubMed Web of Science ®Google Scholar
• SimonAGariépyJMoyseDDifferential effects of nifedipine and co-amilozide on the progression of early carotid wall changesCirculation200110329495411413085
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study GroupEfficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39BMJ1998317713209732338
   PubMed Web of Science ®Google Scholar
• VasanRSLarsonMGLeipEPImpact of high-normal blood pressure on the risk of cardiovascular diseaseN Engl J Med20013451291711794147
   PubMed Web of Science ®Google Scholar
• VerdecchiaPSchillaciGBorgioniCPrognostic significance of serial changes in left ventricular mass in essential hypertensionCirculation19989748549443431
   PubMed Web of Science ®Google Scholar
• VibertiGWheeldonNMMicroalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure-independent effectCirculation2002106672812163426
   PubMed Web of Science ®Google Scholar
• WeberMAJuliusSKjeldsenSEBlood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trialLancet200436320495115207957
   PubMed Web of Science ®Google Scholar
• WilsonAMRyanMCBoyleAJThe novel role of C-reactive protein in cardiovascular disease: risk marker or pathogenInt J Cardiol2006106291716337036
   PubMed Web of Science ®Google Scholar
• ZanchettiABondGHennigMCalcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double blind, long-term trialCirculation20021062422712417537
   PubMed Web of Science ®Google Scholar